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Abstract
Background: Multiple Sclerosis (MS) is the most common cause of neurological disability in young and
middle-aged adults. At this stage in life most people are in the midst of their working career. The majority of MS
patients are unable to retain employment within 10 years from disease onset. Leading up to unemployment, many
may experience a reduction in hours or work responsibilities and increased time missed from work. The MS@Work
study examines various factors that may influence work participation in relapsing-remitting MS patients, including
disease-related factors, the working environment and personal factors.
Methods/design: The MS@Work study is a multicenter, 3-year prospective observational study on work
participation in patients with relapsing-remitting MS. We aim to include 350 patients through 15–18 MS outpatient
clinics in the Netherlands. Eligible participants are 18 years and older, and either currently employed or within three
years since their last employment. At baseline and after 1, 2 and 3 years, the participants are asked to complete
online questionnaires (including questions on work participation, work problems and accommodations, cognitive
and physical ability, anxiety, depression, psychosocial stress, quality of life, fatigue, empathy, personality traits and
coping strategies) and undergo cognitive and neurological examinations. After six months, patients are requested
to only complete online questionnaires. Patient perspectives on maintaining and improving work participation and
reasons to stop working are gathered through semi-structured interviews in a sub-group of patients.
Discussion: Prospective studies with long-term follow-up on work participation in MS are rare, or take into account
a limited number of factors. The MS@Work study provides a 3-year follow-up on various factors that may influence
work participation in patients with relapsing-remitting MS. We aim to identify factors that relate to job loss and to
provide information about preventative measures for physicians, psychologists and other professionals working in
the field of occupational health.
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Background
Multiple Sclerosis (MS) is a chronic, inflammatory, de-
myelinating and degenerative disease affecting the cen-
tral nervous system [1]. MS is the most common cause
of neurological disability in young and middle-aged
adults [2, 3]. At this stage in life most people are at the
beginning or in the midst of their working career. Work
participation is important for a person’s sense of self-
respect, social contacts and providing a feeling of useful-
ness and satisfaction. Job loss has been associated with
worse self-reported health and increased adverse health
behaviors after job loss [4]. A large number of patients
with MS (55-58 %) are unable to retain employment
following diagnosis [5, 6]. In those with a paid job, a re-
duction in hours or work responsibilities, presenteeism
and increased time missed from work can be observed
[7, 8]. From a societal perspective, the loss of productiv-
ity in MS leads to significant socio-economic costs. A
recent Danish study highlighted the economic impact
of costs associated with productivity loss in MS, which
are much higher than the healthcare costs (including
hospitalization costs, outpatient clinic costs, primary
care costs and drug costs) [9]. In fact, employment rate
was found to be affected up to eight years before the
diagnosis of MS. In a Dutch study, it was found that
production losses contribute to a significant proportion
(45.8 %) of the total annual MS-related costs. It should
be noted that these production costs are mainly related
to early retirement due to MS, while costs related to
long-term sick leave and short-term absence contribute
less [10]. The high prevalence of unemployment among
MS patients and the large personal and societal costs
involved underline the need to study factors associated
with unemployment and work absence in MS.
Factors related to unemployment and work absence in
MS
The causes of unemployment in MS involve a complex
interaction between disease-related factors, the working
environment, job demands and personal factors [11].
Many studies on work ability or work status in MS
focus on physical and cognitive measures as primary
determinants of work capacity. Cognitive functions such
as working memory, episodic memory and processing
speed have been identified as important predictors of
employment status [12, 13]. Cognitive functioning re-
mains an important predictor even when controlling for
depression and disease course [12]. A 3-year follow-up
of employed MS patients revealed that cognitive decline,
especially in verbal memory and processing speed, dis-
tinguishes MS patients who progressed to work disability
(28,9 %) from those who did not [14]. The latter study
utilized both a conservative and liberal definition of deteri-
orated employment status. The conservative approach
required a person to deteriorate from being gainfully
employed to being disabled with formal disability benefits
(occurring in 28,9 % of the participants over three years),
while the liberal approach accepted any reduction in hours
or work responsibilities (occurring in 45,5 % of the partici-
pants). A review study found ample support for the influ-
ence of physical functioning (indicated by level of
neurological disability or the number and type of mobility
aids) and cognitive functioning (indicated by memory
functioning, verbal ability and self-perceived cognitive
function) in work ability [15]. However, although limita-
tions in physical and cognitive function hinder an individ-
ual’s ability to work, they cannot solely explain work
capacity [15]. Other factors, such as educational level, type
of work, fatigue, health perception, depression, personality
and type of immunomodulatory treatment are also in-
volved when predicting work participation [3, 8, 16, 17].
A study by Honarmand and colleagues [8] focused
on the influence of neurological, demographic, psy-
chological and cognitive factors on employment status
(i.e. ‘employed’ versus ‘unemployed’) [8]. Cognitive
and physical measures appeared as a robust predictor
of employment status. Interestingly, higher depression
scores and lower scores on the personality constructs
‘agreeableness’ and ‘extraversion’ were also associated
with unemployment. A combination of symptoms of
depression, less agreeableness and lower cognitive and
physical functioning predicted 49,8 % of the variance
in employment status.
The findings of a recent study indicate that already
one year after the diagnosis of clinically isolated syn-
drome and relapsing-remitting MS, power of attention
and memory are associated with a capability of working
less hours, and that fatigue, depression and disease im-
pact may negatively, and self-efficacy positively affect
working hours [18].
The manner of coping with problems also tends to be
a factor influencing work participation. Lode and col-
leagues [19] found that disability pensioned patients
employed more problem-focused, emotion-focused and
avoidant coping strategies than MS patients without a
disability pension. Previous research has shown that
emotion-focused and avoidant coping strategies are con-
sidered dysfunctional in adaptation to a chronic disease
[20, 21].
The working environment is a very important factor
for work participation when diagnosed with MS, includ-
ing environmental factors, social factors, workplace factors
and work demands [11]. Higher odds of unemployment
have been observed in jobs requiring physical strength,
manual precision and frequent moves, while protective
factors include working in the public sector, a desk job or
other sitting work [22]. Other important variables in-
clude accessibility and temperature of the workplace,
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available workplace accommodations (e.g. a flexible
schedule, ergonomic work station, preferred parking),
employer and colleague support, negative work events
and perceived workplace difficulties [11, 23, 24].
Treatment with immunomodulators, including glatira-
mer acetate and the beta-interferons, is widely supported
in relapsing-remitting MS [25]. Evidence suggests that
immunomodulatory treatment reduces disease progres-
sion, as evidenced by a reduction in relapse rate [25] and
less fatigue [26]. Several studies focused on the effects of
immunomodulatory treatment on work absence in MS
[16, 27, 28]. Type of immunomodulatory treatment was
found to affect the number of days missed from work,
although not always in the desired direction. Effects dif-
fered per type of immunomodulatory treatment.
Study objectives and hypotheses
Most evidence for factors associated with work partici-
pation comes from cross-sectional studies. Prospective
studies are rare, or take into account a limited number
of factors. The main aim of the MS@Work study is to
examine predictors of (changes in) employment status
and work absenteeism in relapsing-remitting MS pa-
tients over a period of three years. By taking into ac-
count a wide variety of disease-related, work-related and
personal factors this study may reveal typical patterns
leading to changes in work participation. Identifying
these patterns provides useful information about pre-
ventative factors for physicians, psychologists and other
professionals working in the field of occupational health.
This leads to the following research questions:
(1) Are there differences in cognitive, neurological and
psychological functioning between employed and
unemployed patients at baseline?
(2) What (combination of) cognitive, neurological,
psychological and work-related factors predict
(changes in) employment status and work
absenteeism over a period of three years?
(3) What is the relation between initiating
immunomodulatory treatment and work
participation over a period of three years?
(4) What reasons to stop working are provided
retrospectively by patients with relapsing-remitting
MS?
(5) From a patient perspective: what can be done to
maintain or improve work participation?
Overall, this study is considered exploratory; we in-
clude detailed cognitive, psychological and work-related
measures that have not been studied in the context of
longitudinal work participation. Employment status will
be defined in both a conservative and liberal manner,
and will also pertain to self-employed patients. The
qualitative analyses will give more in-depth information
about factors involved with work participation from a
patient perspective.
Based on existing literature we expect to find more
cognitive, physical and psychological problems in non-
employed as compared with employed MS patients at
baseline. Leading up to a lowered employment status
and more work absenteeism, executive difficulties, in-
creased fatigue, psychological problems and work diffi-
culties are expected to become more apparent. MS
patients receiving immunomodulatory treatment are
expected to miss less days from work and have a more
stable employment status over the 3-year study period,
as compared with relapsing-remitting MS patients re-
ceiving no immunomodulatory treatment. This is ex-
pected to be related to less fatigue symptoms and
relapses in patients treated with immunomodulators.
Methods/design
Design and setting
The MS@Work Study Group is a collaboration between
health care professionals and researchers in the field of
MS, occupational health professionals, and 15–18 MS
outpatient clinics in the Netherlands. At this moment, a
collaboration is set up with 15 MS outpatient clinics
(Albert Schweitzer Ziekenhuis, Dordrecht, Alrijne
Ziekenhuis Leiden, Leiden; Amphia Ziekenhuis, Breda;
Canisius-Wilhelmina Ziekenhuis, Nijmegen; Catharina
Ziekenhuis, Eindhoven; Elisabeth-TweeSteden Ziekenhuis,
Tilburg; Jeroen Bosch Ziekenhuis,’s Hertogenbosch;
Maasstad Ziekenhuis, Rotterdam; Medisch Centrum
Alkmaar, Alkmaar; Medisch Centrum Leeuwarden,
Leeuwarden; Orbis Medisch Centrum, Sittard; Rijnstate
Ziekenhuis, Arnhem; St. Anna Ziekenhuis, Geldrop; St.
Antonius Ziekenhuis, Nieuwegein and VieCuri Medisch
Centrum, Venlo). The MS@Work study is a prospect-
ive, observational cohort study in 350 patients with
relapsing-remitting MS who will be recruited from
outpatient clinics in the Netherlands. Inclusion started
in April 2014.
Study population
Eligible subjects should be diagnosed with relapsing-
remitting MS according to the Polman-McDonald cri-
teria 2010 [29]. Furthermore, we plan to include patients
that are 18 years and older, and either currently
employed or within three years since their last employ-
ment. Patients with comorbid psychiatric or neurological
disorders, substance abuse, neurological impairment that
might interfere with cognitive testing (e.g. inadequate
vision) or unable to speak and/or read Dutch are ex-
cluded from the study. Study visits will be rescheduled
in case of an MS relapse within 1 month prior to the
study visit.
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Sample size calculation
The main aim of the study is to examine predictors of
(changes in) employment status and work absenteeism
in relapsing-remitting MS patients over a period of three
years. For this purpose a logistic regression analysis will
be used. A power analysis based on a 5 % significance
level, 80 % power, and an odds ratio of 2.1 indicates
that at least 300 patients need to be included [30].
Taking into account a longitudinal drop-out rate of
10 % [31], the number of patients should be increased
to a minimum of 330 patients. We aim to include at
least 350 patients.
Data collection, processing and storage
MS patients visiting outpatient clinics in the Netherlands,
who meet the inclusion criteria, will be asked to participate
in the MS@Work study. At baseline and after 1, 2 and
3 years participants will be asked to complete online ques-
tionnaires, and undergo neurological and cognitive exami-
nations. After 6 months, participants only need to fill
online questionnaires without undergoing neurological and
cognitive examinations. Table 1 provides an overview of
data collection per time point.
The inclusion and exclusion criteria will be checked by
a neurologist. Eligible patients will be asked to participate
by a letter explaining the study procedures. The letter
includes an informed consent form, a non-responder ques-
tionnaire and return envelope. Patients who are interested
in participating are asked to send back the signed informed
consent form. After receiving this form, the patient will be
contacted and an appointment will be made for neuro-
logical and cognitive examinations. Patients are asked to
complete several online questionnaires at home. For this
purpose a personalized e-mail will be sent with a link to the
online questionnaires. The questionnaires are to be com-
pleted within one week. Within this time frame the ques-
tionnaire may be filled in at moments that are suitable to
the participant. Their answers will be saved automatically.
In case the questionnaires have not been completed within
one week, a reminder e-mail will be sent. Patients who do
not have internet access, or who are not capable of
using a PC are sent a paper-and-pencil version of the
questionnaires. The neurological and cognitive exami-
nations should be performed on one day, and should
preferably take place at the outpatient clinic where the
patient is treated.
The neurological examination will be performed by a
neurologist or a neurologist in training. Psychologists or
trained research nurses will perform the cognitive exam-
inations. Patients will be offered a financial compensa-
tion for traveling expenses. With the patient’s approval,
the general practitioner will be informed of the patient’s
participation in the MS@Work study. The outpatient
clinics will be asked to keep track of the number of pa-
tients that are invited to participate. Patients who do not
wish to participate are asked to complete a brief non-
responder questionnaire. This questionnaire will later be
used to compare non-responders and responders on age,
gender and job characteristics. A subgroup of 20 patients
will be interviewed by one researcher to assess in a
qualitative way the most important factors involved in em-
ployment from a patient perspective and (if applicable) their
reasons for discontinuing employment.
The neurological and cognitive scoring forms are
stored at the MS outpatient clinics. After completion of
the study, the gathered data and scoring forms will be
stored at the Faculty of Social Sciences (Leiden University)
for a period of five years. An SPSS data file (IBM SPSS
statistics 19) will be created in which the data are
stored anonymously. Each patient will receive a personal
code and any identifying information is removed from the
source file. The source file will be accessible to the principal
investigators upon request. Student assistants participating
in data collection will be provided temporary access to the
database. The key database and source file will both be
safeguarded by the coordinating investigator.
Materials/Measures
Neurological examination
In a structured interview data will be collected on dis-
ease course, relapse rate, time of last relapse, current
and previously used medication, co morbid neurological
and psychiatric disorders, substance abuse and neuro-
logical impairment that might interfere with cognitive
testing (e.g. inadequate vision). The examination further
includes the Expanded Disability Status Scale [32] and the
Multiple Sclerosis Functional Composite [33] which com-
bines the 9-Hole Peg Test [34] for assessing arm and hand
function, the Timed 25-foot walk [35] for assessing mobil-
ity and leg function, and the Paced Auditory Serial
Addition Test [36] (see cognitive examination).
Cognitive examination
An overview of the administered tests and correspond-
ing cognitive domains is provided in Table 2. The cogni-
tive examination consists of task representing cognitive
Table 1 Flowchart data collection
Baseline 6 months 1 year 2 years 3 years
Informed consent X X (online) X (online) X (online) X (online)
Online
questionnaires
X X X X X
Neurological
examination
X X X X
Cognitive
examination
X X X X
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domains like memory, processing speed, verbal word flu-
ency, visual spatial processing and higher executive func-
tioning. Most subtests of the Minimal Assessment of
Cognitive Function in Multiple Sclerosis (MACFIMS)
[12], the Trail Making Test [37] and subtests of the
Delis-Kaplan Executive Function System [38] are used.
Questionnaires
The online questionnaires and the constructs they in-
tend to measure are listed in Table 3. The Work Role
Functioning Questionnaire and work-related questions
in the general questionnaire are intended for participants
with a paid job. The Multiple Sclerosis Neuropsychological
Screening Questionnaire is intended for patients and infor-
mants. The Caregiver Strain Index and Neuropsychiatric
Inventory are intended for the caregiver or informant.
The NEO Five-Factor Personality Inventory is only
administered at baseline. In working-age adults the big-
five personality traits are considered stable over a four-
year period [39].
Statistical analyses
Statistical analyses will be performed using SPSS 21.0
(Statistical Package for the Social Sciences version
21.0, IBM, Chicago, Illinois, USA). ATLAS.ti (ATLAS.ti
Scientific Software Development GmbH, Berlin, Germany)
will be used to perform qualitative data analyses.
Predictors of work participation
Depending on the distribution of the data, independent
t-tests, analysis of covariance (ANCOVA), Mann–Whitney
U and Chi-square tests will be used to examine baseline
differences in cognitive, neurological and psychological var-
iables (dependent variables) between employed and un-
employed relapsing-remitting MS patients (independent
Table 2 Cognitive test battery
Test Cognitive domain(s)
Visual Analogue Scale Fatigue and energy (before and after examination)
Controlled Oral Word Association Test [41] Verbal word fluency
Semantic Category Fluency [42] Verbal word fluency
Judgment of Line Orientation Test [41] Visual-spatial processing
Rey Verbal Learning Test [43, 44] Learning and memory
Brief Visuospatial Memory Test-Revised [45] Learning and memory
Symbol Digit Modalities Test [46] Information processing speed and working memory
Paced Auditory Serial Addition Test [36] Information processing speed, flexibility and working memory
Trail Making Test [37] Information processing speed, attention and concept shifting and
executive functioning
Delis-Kaplan Executive Function System Design Fluency Test [38] Fluency in generating visual patterns, response inhibition and
executive functioning




General questionnaire Demographics, disease
characteristics, medication,
characteristics of current and
previous jobs, absenteeism,

















Modified Fatigue Impact Scale-20 [52] Fatigue impact
Checklist Individual Strength-20-R [53] Fatigue
Every Day Problem Checklist [54] Chronic everyday stress




Coping Inventory for Stressful
Situations [57]
Coping strategies
Empathy Quotient [58] Empathy
Multiple Sclerosis Work Difficulties
Questionnaire [24]
Work difficulties
Caregiver Strain Index [59] Caregiver Strain
Neuropsychiatric Inventory [60] Neuropsychiatric problems
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variable). Logistic regression analyses will be used to study
predictors (cognitive, neurological, psychological and
work-related factors) of employment status (i.e. employed
versus unemployed/deteriorated versus stable) in
relapsing-remitting MS patients with a paid job after 1, 2
and 3 years. Multiple regression analysis will be performed
to study associations between cognitive, neurological, psy-
chological and work-related factors (independent variables)
and work absenteeism (dependent variable) in relapsing-
remitting MS patients with a paid job after 1, 2 and 3 years.
Repeated measures analysis of variance will be used to
examine cognitive, neurological and psychological changes
over a period of three years (within-subject factor) in
relapsing-remitting MS patients who lose employment, ver-
sus those who retain employment, versus those who remain
unemployed (between-subjects factor).
Immunomodulatory treatment and work participation
Treatment naive patients initiating treatment with an
immunomodulator (i.e. interferon beta-1a, interferon
beta-1b and glatiramer acetate) will be compared with
treatment naive relapsing-remitting MS patients not
initiating immunomodulatory treatment. Treatment
naive in this context is defined as not previously treated
with an immunomodulatory treatment. Depending on
the distribution of the data, independent t-tests,
ANCOVA, Mann–Whitney U, and Chi-square tests will
be used to examine differences in employment status
and work absenteeism (dependent variables) between
patients initiating immunomodulatory treatment and pa-
tients not initiating this type of treatment (independent
variable). Tests will be performed after 6 months, 1, 2
and 3 years. A paired samples t-test will be used to com-
pare work absenteeism before and after starting immu-
nomodulatory treatment after 6 months, 1, 2 and
3 years. Separate analyses will be performed for each
type of immunomodulatory treatment. On an explora-
tory basis, we will examine changes in fatigue and phys-
ical disability before and after treatment.
Qualitative analyses of semi-structured interviews
To access meanings, structures and essences of employ-
ment 20 semi-structured interviews will be conducted.
The research design moves from lower-level analysis to
higher-level theorizing. As research-strategy, Grounded
Theory will be used. For detailed exploration of the data,
quantitative analysis and Interpretative Phenomenological
Analysis (IPA) will be used.
Ethical considerations
The study was approved by the Medical Ethical Commit-
tee Brabant (NL43098.008.12 1307) and the Board of
Directors of the participating MS outpatient clinics. The
study will be conducted according to the principles of
the Declaration of Helsinki (amended by the 64th WMA
general Assembly, Fortaleza, Brazil, October 2013) and
in accordance with the Medical Research Involving
Human Subjects Act (WMO) [40].
Discussion
The MS@Work study provides a 3-year follow-up on
various factors that may influence work participation in
patients with MS. Key strengths of the study are its
multi-factorial approach and longitudinal design. We in-
clude several disease-related, work-related and personal
factors, that have rarely been studied in combination or
longitudinally. By examining the patients’ physical and
mental well-being and their (work) situation at regular
time intervals, we aim to reveal typical patterns leading
to changes or stability in work participation. This can be
viewed in terms of job loss, but also in terms of which
conditions should be met to maintain a job or to attain
one. Another strength is our use of different (operational)
definitions of work participation and related constructs,
such as work ability, work-related problems, important
job aspects and the need for accommodations.
Qualitative data analyses will be used to examine pa-
tient perspectives on what can be done to improve
work participation and reasons to stop working. This
may provide unique insights in the current socio-
economic climate, that may or may not be beneficial
for work participation in patients with a chronic dis-
ease such as MS. Potential study limitations include a
selection bias; only relapsing-remitting MS patients
are included who visit outpatient clinics in the
Netherlands. We specifically chose to include patients
with a relapsing-remitting disease course, as these are
generally ambulatory and there is a higher possibility
of work participation. This study will be carried out
in a Dutch health care and social security context.
Generalization of results to other contexts may be
limited.
More than half of the people diagnosed with MS are
unable to retain employment which is associated with
high socioeconomic costs. Combined with the fact that
work participation is not only important for a person’s
financial security, but also for one’s sense of self-respect,
social engagement and feelings of usefulness, the need to
research factors influencing work participation in MS is
eminent. The MS@Work study provides an excellent
starting point for future research on work participation
in MS. As the study aims to provide information about
preventative factors for job loss, the outcomes may be
used to design job training programs for MS patients
and to design effective strategies to inform both patients
and employers how to help MS patients maintain their
jobs.
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